Skip to main content

Table 3 Disease activity and function before and after weight loss treatment in 41 patients with PsA

From: Weight loss improves disease activity in patients with psoriatic arthritis and obesity: an interventional study

  Baseline
Median (IQR)
Min–max
6 months
Median (IQR)
Min–max
p value
Weight, kg 106.3 (95.8–113.6)
84–124
82.9 (76.4–92.1)
61.3–107.4
< 0.001
BMI, kg/m2 35.2 (34.1–38.1)
33.0–45.8
29.8 (26.6–31.5)
23.1–37.0
< 0.001
Waist circumference, cm 116 (112–122)
103–135
95.5 (89–103)
81–116
< 0.001
CRP, mg/L 4 (2–8.5)
1–50
2 (1–6.5)
1–50
0.041
Hemoglobin, g/L 144 (132–150)
116–179
141 (131.5–148)
118–161
0.047
WBC, 109/L 5.9 (5.2–7.6)
4.3–15.2
5.9 (5.0–6.8)
(3.2–12.7)
0.062
PLT, 109/L 270 (204–300)
174–444
230 (186–290)
156–402
< 0.001
Tender joints 68, score 4 (1–14)
0–30
2 (0–6.5)
0–19
< 0.001
Swollen joints 66, score 0 (0–1)
0–5
0 (0–0.5)
0–7
0.021
VAS patients global disease activity, mm 34 (19–61)
0–93
12 (5–51)
0–95
0.001
VAS pain, mm 30 (18.5–62.5)
0–95
20 (5–51.5)
0–95
0.004
VAS fatigue, mm 56 (21.5–67)
0–94
25 (8–44)
0–98
0.001
DAS28CRP, score 2.9 (2.1–3.7)
1.4–5.6
2.4 (1.7–3.0)
1.2–4.5
< 0.001
DAPSA, score 15.3 (6.6–29.1)
0.9–46
11.0 (2.8–17.6)
0.2–35
< 0.001
Leeds enthesitis index 1 (0–4)
0–6
0 (0–3)
0–4
0.001
BSA, % 1.6 (0–2.2)
0–10
0.9 (0–1.1)
0–5.5
0.014
HAQ, score 0.70 (0.13–1.00)
0–2.63
0.43 (0–0.69)
0–1.88
< 0.001
DLQI, score 1 (0–4.5)
0–17
1 (0–4)
0–20
0.453
  1. BMI body mass index, BSA body surface area, CRP C-reactive protein, DAPSA Disease Activity in PSoriatic Arthritis, DAS28CRP Disease Activity Score using 28 joint counts based on CRP, DLQI Dermatology Life Quality Index, PLT platelet count, WBC white blood cell count